Tirofiban

• Fibrinolytic Agents
• Platelet Aggregation Inhibitors
• ATC:B01AC17

• AGG
• Aggrastat
• Tirofiban [BAN:INN]

• No information avaliable

C₂₂H₃₆N₂O₅S

http://www.rxlist.com/cgi/generic/tiro.htm

Tirofiban FDA

No information avaliable

440.598 g/mol

No information avaliable

Very slightly soluble

Solid

3.54

Liquid; Solution

For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.

Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. When administered intravenously, tirofiban inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, >90% inhibition is attained by the end of the 30-minute infusion. Tirofiban has been recently shown in patients with unstable angina to reduce ischemic events at 48 hours following infusion when compared to standard heparin therapy.

No information avaliable

No information avaliable

Follow all instructions for proper mixing or dilution (if necessary) and refer to the tirofiban dosing chart for the recommended IV dosing. If you have questions regarding the use of this medication, consult your pharmacist. Give this medication by vein (IV) as an initial dose (bolus dose) followed by an IV infusion as directed by your doctor. The dosage is based on your weight, medical condition, and response to therapy. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard needles and medical supplies safely. Consult your pharmacist.

Humans and other mammals